IPA to Present at The Microcap Conference 2025
ImmunoPrecise Antibodies (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, has announced its participation in The Microcap Conference 2025. The event will be held from January 28-30, 2025, in Atlantic City, NJ. During the conference, IPA's management team will deliver a corporate presentation and conduct one-on-one meetings with institutional and individual investors to showcase the company's recent developments, growth strategy, and investment opportunities.
ImmunoPrecise Antibodies (NASDAQ: IPA), una azienda di ricerca e tecnologia bioterapeutica alimentata dall'IA, ha annunciato la sua partecipazione a The Microcap Conference 2025. L'evento si terrà dal 28 al 30 gennaio 2025, ad Atlantic City, NJ. Durante la conferenza, il team gestionale di IPA presenterà un intervento aziendale e condurrà incontri individuali con investitori istituzionali e privati per illustrare gli sviluppi recenti dell'azienda, la strategia di crescita e le opportunità di investimento.
ImmunoPrecise Antibodies (NASDAQ: IPA), una empresa de investigación y tecnología bioterapéutica impulsada por IA, ha anunciado su participación en The Microcap Conference 2025. El evento se llevará a cabo del 28 al 30 de enero de 2025, en Atlantic City, NJ. Durante la conferencia, el equipo directivo de IPA ofrecerá una presentación corporativa y realizará reuniones individuales con inversores institucionales y particulares para mostrar los desarrollos recientes de la empresa, su estrategia de crecimiento y las oportunidades de inversión.
ImmunoPrecise Antibodies (NASDAQ: IPA), AI 기반의 생물의약품 연구 및 기술 회사,가 The Microcap Conference 2025에 참여할 것이라고 발표했습니다. 이 행사는 2025년 1월 28일부터 30일까지 뉴저지주 애틀랜틱 시티에서 개최됩니다. 회의 중에 IPA의 경영진은 기업 발표를 진행하고 기관 및 개인 투자자와의 일대일 미팅을 통해 회사의 최근 발전, 성장 전략 및 투자 기회를 소개할 예정입니다.
ImmunoPrecise Antibodies (NASDAQ: IPA), une entreprise de recherche et de technologie biothérapeutique guidée par l'IA, a annoncé sa participation à The Microcap Conference 2025. L'événement se déroulera du 28 au 30 janvier 2025, à Atlantic City, NJ. Pendant la conférence, l'équipe de direction d'IPA fera une présentation d'entreprise et organisera des réunions individuelles avec des investisseurs institutionnels et particuliers pour mettre en avant les récents développements de l'entreprise, sa stratégie de croissance et les opportunités d'investissement.
ImmunoPrecise Antibodies (NASDAQ: IPA), ein auf KI basierendes Unternehmen für biotherapeutische Forschung und Technologie, hat seine Teilnahme an The Microcap Conference 2025 angekündigt. Die Veranstaltung findet vom 28. bis 30. Januar 2025 in Atlantic City, NJ, statt. Während der Konferenz wird das Management-Team von IPA eine Unternehmenspräsentation halten und Einzelgespräche mit institutionellen und privaten Investoren führen, um die jüngsten Entwicklungen des Unternehmens, die Wachstumsstrategie und Investitionsmöglichkeiten vorzustellen.
- None.
- None.
IPA’s management team will deliver a corporate presentation and engage in one-on-one meetings with institutional and individual investors to discuss the company’s recent developments, growth strategy, and investment opportunities.
About The Microcap Conference 2025
The Microcap Conference is the largest independent microcap event in the
The 2025 event will feature:
- Keynote Speakers: Renowned industry figures, including Jon Ledecky, Co-Owner of the New York Islanders, who will engage in a fireside chat with CNBC’s Bob Pisani; plus Tom Gardner, CEO of Motley Fool, who will share insights on investing, market trends, and entrepreneurial success.
- Expert Panels and Presentations: Financial commentators Ron Insana (CNBC) and Charlie Gasparino (FOX Business) will cover critical topics for the US equity markets, from capital formation to regulatory updates and market trends.
- Entertainment Headliner: A special performance by Tom Papa, celebrated comedian and host of Netflix specials, ensuring a memorable evening for attendees.
Hosted by DealFlow Events, The Microcap Conference is renowned for its blend of high-quality content, engaging networking, and exceptional entertainment. For more information, visit https://themicrocapconference.com.
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and is known for solving very complex industry challenges. IPA has several subsidiaries in
View source version on businesswire.com: https://www.businesswire.com/news/home/20241219008253/en/
Investor Relations Contact
investors@ipatherapeutics.com
Source: ImmunoPrecise Antibodies Ltd.
FAQ
When and where is IPA presenting at The Microcap Conference 2025?
What will IPA's management team discuss at The Microcap Conference 2025?
What type of investors will IPA meet at The Microcap Conference 2025?
What is the significance of IPA's participation in The Microcap Conference 2025?
What is IPA's business focus as presented at The Microcap Conference 2025?
